Objective: Frataxin (FXN) is a highly conserved mitochondrial protein.
Reduced FXN levels cause Friedreich ataxia, a recessive neurodegenerative disease. Typical patients carry GAA repeat expansions on both alleles, while a subgroup of patients carry a missense mutation on one allele and a GAA repeat expansion on the other. Here, we report that selected disease-related FXN missense mutations impair FXN localization, interaction with mitochondria processing peptidase, and processing. Methods: Immunocytochemical studies and subcellular fractionation were performed to study FXN import into the mitochondria and examine the mechanism by which mutations impair FXN processing. Coimmunoprecipitation was performed to study the interaction between FXN and mitochondrial processing peptidase. A proteasome inhibitor was used to model traditional therapeutic strategies. In addition, clinical profiles of subjects with and without point mutations were compared in a large natural history study. G130V and FXN I154F mutations demonstrates a lower severity compared with other individuals with Friedreich ataxia. Interpretation: These data suggest that the effects on processing associated with FXN G130V and FXN I154F mutations lead to higher levels of partially processed FXN, which may contribute to the milder clinical phenotypes in these patients.
Introduction
Friedreich ataxia (FRDA) affects about one in every 50,000 people in the United States. This slowly progressive ataxia frequently begins in the first decade of life and is associated with dysarthria, spasticity in the lower limbs, scoliosis, absence of lower limb reflexes, and loss of position and vibration sense. [1] [2] [3] At present, there is no cure or effective treatment. FRDA is characterized by decreased expression of the mitochondrial FXN protein, from the frataxin gene on chromosome 9. FXN is important for proper mitochondrial function, but the mechanism by which decreased expression leads to disease pathology is not entirely known. 4 FRDA is most commonly caused by an expansion of a GAA repeat tract in the first intron of the FXN gene on both alleles, and less commonly by a GAA repeat on one allele accompanied by a point mutation in the other FXN allele. In typical FRDA, the length of the shortest GAA expansion correlates with disease severity; longer GAA expansions result in earlier onset and a faster progression. [5] [6] [7] The phenotype of patients who carry a GAA expansion on one allele and a missense mutation on the other allele cannot be predicted with certainty; these patients can have a mild or severe clinical outcome, 8 creating a unique platform to understand clinical and genetic heterogeneity. In general, patients carrying This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
G130V mutations have milder phenotypes in single case reports and small series. In contrast, individuals with mutations in W155R and R165C have much more severe phenotypes. [9] [10] [11] [12] Upon entry into the mitochondria, FXN 1-210 is processed by mitochondria processing peptidase (MPP) into FXN 42-210 , followed by FXN 81-210 . Many missense mutations in the C-terminus end of FXN have been identified in FRDA, yet, few have been characterized in vivo or in situ. Some are proposed to disrupt mRNA expression (various splice site mutations such as c.165 + 1 G>A and c.384 À2 A>G), 11, 12 translation initiation (c.1A>T, c.2T>C, c.2delT, c.3 g>T, c.3G>A), or protein folding (L106S). 9, [13] [14] [15] These should produce little to no functional protein, and their associated phenotype should be severe in conjunction with a long GAA repeat on the other FXN allele. In contrast, R165C, W155R, G130V, and I154F mutations are suspected to produce stable protein. However, R165C and W155R lead to biochemical deficiencies in vitro. 16, 17 The mechanism behind the disease-causing features of G130V and I154F is less clear, having been suggested to reflect abnormal maturation or dysfunctional FXN in different models. 9 In the present study, we have ascertained the features of these mutants in mammalian cell systems to understand from a cellular perspective how they might lead to dysfunction in FRDA.
Methods

Site-directed mutagenesis
Each FXN mutant was created using the pcDNA3.1 plasmid with wild-type human FXN containing a C-terminus hemagglutin (HA) tag (Addgene Plasmid #31895) and the Agilent QuikChange XL Site-Directed Mutagenesis Kit.
Transfection and immunostaining
Human embryonic kidney (HEK 293) cells were grown on coverslips and transfected via Lipofectamine 2000 reagent with 4 lg of DNA (2 lg FXN and 2 lg mito-GFP). Twenty-four hours after transfection, cells were fixed with 4% paraformaldehyde followed by treatment with blocking buffer containing 5% normal goat serum, 3% Triton X-100, and 1% BSA. Primary antibody to the HA epitope was added at a 1:100 dilution overnight. Alexa Fluor 568 secondary antibody was added at a dilution of 1:100 and cells were imaged by confocal microscopy.
Subcellular fractionation and western blot
Following transfection of FXN-mutant constructs, HEK 293 cells were lysed with buffer containing: 150 mmol/L sodium chloride, 1 mmol/L EDTA, 100 mmol/L TrisHCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate, and protease inhibitor cocktail (Millipore #539134) 1:1000 at pH 7.4 for 1 h and centrifuged at 150g to collect whole cell lysates. Whole cell lysates were centrifuged at 100g followed by 150g to separate the soluble mitochondria fraction from the cytosolic fraction, and 100g to collect insoluble mitochondria pellet from soluble mitochondria fraction using a Thermo Scientific Mitochondria Isolation Kit for Mammalian Cells (#89874). The protein concentration of each fraction was determined using a BCA protein assay, and 4 lg of each fraction was loaded on a 12% NuPage gel for electrophoresis, followed by transfer to nitrocellulose membranes. Membranes were blocked with 3% milk for 1 h and incubated with primary HA antibody overnight at 4°C. Membranes were then incubated with secondary HRP-conjugated antibody for 2 h and immunoreactive bands were visualized using luminol-enhanced chemiluminescence (ECL) HPR substrate.
Coimmunoprecipitation and western blot
Twenty-four hours after transfection, cells were lysed with buffer containing: 150 mmol/L sodium chloride, 1 mmol/L EDTA, 100 mmol/L Tris-HCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate, and protease inhibitor cocktail (Millipore #539134) 1:1000 at pH 7.4 for 1 h. For coimmunoprecipitation, 2 lg of MPP primary antibody was added to 800 lg of total lysate and rocked for 2 h at 4°C. The lysate and antibody solution was then added to washed Protein G Agarose beads overnight, rocking back and forth at 4°C. The following day the beads, lysate, and antibody solution were centrifuged at 14,000g and washed five times with IP lysis buffer containing: 150 mmol/L sodium chloride, 1 mmol/L EDTA, 100 mmol/L Tris-HCl, 1% Triton X-100, and 0.5% sodium deoxycholate at pH 7.4. Sample buffer (2X) was added to the beads and heated to 100°C for 5 min. The immunoprecipitated proteins were loaded on a 12% NuPage gel. Normal IgG primary antibody was used as a control as well as anti-FXN primary antibody, followed by Trueblot secondary HRPconjugated antibody (Rockland #18-8841-31) to detect immunoreactive bands.
MG132 Treatment
Transfected cells were treated with 10 lmol/L of MG132, cell-permeable proteasome inhibitor, for 5 h. Following cell lysis, equal amounts of total cell lysate were loaded on a 12% NuPage gel.
Fibroblast FXN levels by Western Blot
Fibroblast cells from healthy controls and FRDA patients with point mutations were lysed in buffer (0.25 mol/L NaCl, 5 mmol/L EDTA, 50 mmol/L HEPES [pH 7.5], 0.1% NP-40, 0.5 mmol/L DTT) supplemented with 0.1% protease inhibitor cocktail (Sigma Aldrich) and kept on ice for 20 min. The lysates were centrifuged at 20,000g for 10 min at 4°C. The clarified supernatants were transferred to fresh tubes and protein concentrations were determined by Bradford assay. A quantity of 75 lg of whole cell lysate were separated by SDS-PAGE and transferred to a PVDF membrane. Immunoblotting was performed with antibodies against FXN (Santa Cruz Biotechnology) and GAPDH (Millipore), and the signals were detected by HRP-mediated chemiluminescence. Densitometry was performed using Image J software (NIH), and the calculated signal ratio of FXN 42-210 to FXN 81-210 in each group is plotted. The bars represent the average signal for each group: CTRL= 5 fibroblast lines (n = 13), G130V =3 lines (n = 17), and Typical = 7 lines (n = 8). The asterisk indicates significant differences as determined by Student's t-test (P < 0.05).
Quantification and statistical analysis
Image J Software was used to quantify FXN levels on western blots and is represented as mean AE SEM. Twotailed Student's t-test was used to compare mutants to WT. Significance was set at P < 0.05. Image J software was also used to calculate Pearson's correlation coefficient for quantification of colocalization in immunofluorescence images.
Clinical measures
Clinical measure results were derived from a long-standing natural history study from 12 American and Australian sites. 18 In this study, data is collected annually on clinical features of > 900 individuals with FRDA. Data from the baseline cross sectional visits were used in this study including overall medical history and scores on the Friedreich Ataxia Rating Scale (FARS) (a quantified neurological exam); Ataxia Staging scale (a disability score); the Timed 25-Foot Walk (T25FW), scored as the reciprocal (a simple performance test of walking); 9-Hole Peg Test (9HPT), scored as the reciprocal (a simple test of hand function); Contrast Letter Acuity test, the sum of the number of letters read on each of three Sloan charts (a quantitative test of vision); and an Activities of Daily Living (ADL) scale. All these measures capture progressive neurological dysfunction in FRDA. The performance measures were also transformed into Z-scores to create composite scores as reported previously. The Z 2 composite is the sum of the Z-scores from T25FW and 9HPT. The Z 3 composite is the sum of Z-scores from T25FW, 9HPT, and overall vision tests. ( Fig. 3E-G) , suggesting these proteins remain associated with the insoluble inner mitochondrial membrane rather than being released into the soluble portion of the mitochondrion. is increased in FRDA G130V patient fibroblasts compared to controls (P < 0.05). Patient fibroblasts were also immunostained with antibodies to FXN and mitofusin. FRDA G130V patient fibroblasts contain large globular structures (Fig. 6B ) consistent with the increased insoluble FXN 42-210 form detected by western blot and overexpression studies.
Results
FRDA patients with FXN
G130V have milder disease features and slower disease progression compared to other heterozygous FRDA patients
We then sought to establish whether patients carrying missense point mutations displayed distinct clinical Pearson's correlation scatter plots of red and green signal intensities for each mutant were generated using Image J Software.
abnormalities that could be related to the altered processing observed in vitro. Heterozygous (HTZ subjects) FRDA patients, with a missense mutation on one FXN allele and GAA expansion on the other, and typical homozygous (HMZ subjects) FRDA patients, with GAA expansions on both FXN alleles, have different clinical profiles when examined in a large natural history study (Table 1) . In addition, patients carrying G130V mutations have . Following transfection of mutant constructs in HEK 293 cells, whole cell lysates were centrifuged to perform subcellular fractionation of soluble mitochondria fraction and insoluble mitochondrial pellet. A. FXN levels were detected by western blot using an anti-FXN antibody. Anti-SDHA antibody was used to detect SDHA as a mitochondria marker and loading control. . F. Percent insoluble FXN . G. Total FXN . (*) = P < 0.05 and (***) = P < 0.005. significantly lower occurrence of cardiomyopathy, scoliosis, and diabetes, the most severe components of the disease, compared to other HTZ subjects (Table 1) . Furthermore, clinical measures at baseline exam including ataxia stage, activities of daily living (ADL) scores, 9HPT-1, T25FW-1, Vision, 9HPT, Z2, and Z3 were significantly worse in other HTZ subjects, even though the groups were of similar disease duration, suggesting a less severe phenotype in G130V patients (Table 2) . Patients with an I154F mutation fell between the phenotypic severity of G130V and other point mutations analyzed.
Discussion
This study shows that the FRDA-causing mutations FXN G130V levels, but does increase levels of FXN . These are all consistent with a defect in peptide processing of these forms being a pathogenic mechanism in patients carrying these mutations. In addition, these two forms, especially G130V, are associated with milder features of FRDA than other point mutations or expanded GAA repeats, suggesting that these mild phenotypes may reflect the underlying FXN biochemistry.
In heterologous systems, disease-associated mutations in FXN are abnormal in several mutation selective ways. The inability to detect FXN L106S and FXN G137V by immunostaining and western blot supports modeling studies suggesting that mutations residing within the protein core decrease protein stability. 9 In vitro functional studies have also characterized FXN R165C may provide a correlation between the extent of dysfunction in these two FXN-mutant proteins and severity of disease outcome. Abnormalities in FXN processing have been explored mostly in yeast and bacteria expression systems. 14, [19] [20] [21] Here, we show an increased level of the FXN 42-210 form in disease-associated missense mutations associated with milder phenotypes, not only in overexpression studies using mammalian systems, but also in primary fibroblasts from FRDA patients. FRDA patients who carry G130V express lower FXN 81-210 levels than typical FRDA patients in fibroblasts, cheek swabs, and blood, 22 yet have a milder clinical phenotype (Tables 1 and 2 ). In a large cohort of FRDA subjects, even though those with the G130V mutation have similar disease duration, they have significantly better FARS and ADL scores than individuals with other point mutations. FRDA G130V patients also have significantly lower occurrence of cardiomyopathy, scoliosis, and diabetes, and they surpass other point mutation carrying subjects on composite performance measures. As suggested in single cases previously, this demonstrates that FRDA patients with FXN G130V demonstrate greater neurological function and decreased disease severity at a similar length of disease duration. 8, 10, 11, 15, [23] [24] [25] [26] [27] [28] [29] . FXN levels were quantified by western blot using whole cell extracts from control (CTRL), FRDA, and G130V patient fibroblasts. CTRL= 5 fibroblast lines (n = 13), G130V =3 lines (n = 17), and Typical = 7 lines (n = 8). A. . (*) = P < 0.05. B. Confocal microscopy images of patient fibroblasts (CTRL, FRDA, and G130V) that were fixed and stained using primary anti-FXN and primary antimitofusin antibodies. Secondary antibodies included Alexa Fluor 568 (FXN) and Alexa Fluor 488 (mitofusin). DAPI was also used as a nuclear stain. Patients who were heterozygous (HTZ) for the GAA repeat (those carrying point mutations or deletions) had similar disease durations to those who were homozygous (HMZ), but, aside from age of onset and presence of diabetes, were less severely affected than homozygous patients. This was particularly true for measures containing upper extremity function such as the nine-hole peg test and the Z2 score. *P < 0.05.
heterologous systems by which FXN point mutations can lead to FRDA. 
